Welcome to Markets Desk, your midday read on what's moving markets and the broader economy.
Two economists are sounding a structural alarm on artificial intelligence adoption, warning that companies racing to replace workers with AI may be sawing off the branch they're sitting on. The argument is straightforward: erode the wage base broadly enough, and you erode the consumer demand that justifies corporate revenue in the first place. The World Economic Forum has echoed the concern, noting that AI disruption is outpacing reskilling efforts at nearly every level of the workforce.
Shifting to aerospace, Boeing and Airbus are both quietly advancing designs for their next generation narrow-body aircraft, but the market isn't asking for them yet. Airlines and their investors remain laser-focused on production reliability and near-term deliveries from existing programs. Until both manufacturers demonstrate they can execute consistently on current commitments, next-generation promises carry limited weight on a balance sheet.
And on the pharmaceutical side, new academic research out of Denmark is putting hard labor-market numbers behind GLP-one treatments like Semaglutide. The study finds that patients initiating treatment early showed meaningful reductions in long-term sickness leave, a data point that carries real implications for productivity assumptions, insurance modeling, and the broader economic case for employer coverage of these drugs.
That's the tape. Markets Desk, signing off the floor.
